Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 131 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Calcium or Placebo Clear all

Conditions: Sepsis, Acute Lung Injury
Interventions: Rosuvastatin, Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 745 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 40
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 20 more

Conditions: Osteoporosis
Interventions: Calcium Chloride/Calcium Gluconate, Half-Normal Saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years to 80 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cystic Fibrosis
Interventions: Recombinant Human DNase (Pulmozyme), Placebos; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Month to 30 Months
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Autism Spectrum Disorder, Language Disorders
Interventions: Levoleucovorin Calcium, Placebo; Drug · Other
Lead sponsor: Southwest Autism Research & Resource Center; Other
Eligibility: 30 Months to 60 Months
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Brooklyn, New York

Conditions: Lupus Erythematosus, Systemic
Interventions: Atorvastatin, Placebo atorvastatin; Drug
Lead sponsor: Laura Schanberg; Other
Eligibility: 10 Years to 21 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
Interventions: rosuvastatin, placebo; Drug
Lead sponsor: Susan Smyth; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more

Conditions: Apical Periodontitis, Endodontically Treated Teeth, Endodontic Disease, Apical Cyst, Apical Granuloma, Periradicular Disease, Previous Endodontic Treatment
Interventions: PBM treatment, PBM sham treatment, EMS; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: New Biomarkers for Measuring Vitamin D Level
Interventions: Vitamin D Supplementation, Placebo, Calcium; Dietary Supplement · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 444 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Breast Neoplasms, Osteoporosis
Interventions: Zoledronic Acid, Letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 43
States / cities: Springdale, Arkansas • Burbank, California • Lafayette, California + 39 more

Conditions: Overweight and Obesity, Eating Behavior
Interventions: Placebo, Bromocriptine-QR; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Essential Tremor
Interventions: 100 mg PRAX-944, 60 mg PRAX-944, Placebo, Flexibly dosed 20 mg to 100 mg PRAX-944; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 31 more

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Interventions: Pembrolizumab, Placebo, Cisplatin, Capecitabine, 5-fluorouracil, Docetaxel, Oxaliplatin, Leucovorin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 14
States / cities: Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 7 more

Conditions: Sleep Disturbance, Sleep Quality
Interventions: 2 mg THC + 2 mg CBN + 2 mg CBG + 10 mg CBD + 1 mg Melatonin, 10 mg THC + 5 mg CBN + 5 mg CBG + 20 mg CBD, 10 mg THC + 20 mg CBN + 5 mg CBG, Stay Asleep Placebo, Fast Asleep Placebo; Dietary Supplement
Lead sponsor: Cannabis Science Innovations, LLC; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 332 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Sarasota, Florida

Conditions: Kidney, Polycystic
Interventions: Lisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 15 Years to 64 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more

Conditions: Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
Interventions: pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 19
States / cities: Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more

Conditions: Wounds and Injuries, Venous Thromboembolism
Interventions: Aspirin and Rosuvastatin, Placebo (for Aspirin and Rosuvastatin); Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Osteoporosis (Senile)
Interventions: doxercalciferol capsules, Hectorol®, Matched Placebo (Capsules); Drug
Lead sponsor: Creighton University; Other
Eligibility: 60 Years to 78 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 1994
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Autism Spectrum Disorder, Language Disorders
Interventions: Levoleucovorin Calcium, Placebo; Drug · Other
Lead sponsor: Southwest Autism Research & Resource Center; Other
Eligibility: 30 Months to 60 Months
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Phoenix, Arizona • Brooklyn, New York

Conditions: Anorexia Nervosa
Interventions: RhIGF-1 with transdermal 17-beta estradiol, Placebo and transdermal 17-beta estradiol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 22 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Post-ERCP Acute Pancreatitis
Interventions: Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo; Drug
Lead sponsor: The Cooper Health System; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Tonsillectomy
Interventions: Celecoxib, Placebo, Acetaminophen, Oxycodone; Drug · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 3 Years to 11 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Cancers, Hematologic Disorder, Solid Tumors
Interventions: Dexamethasone, Placebo, Questionnaires, Spirometer, Phone Calls; Drug · Behavioral · Device + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Venous Thromboembolism, Cancer, Cardiovascular Events
Interventions: Rosuvastatin, Placebo Drug; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 9
States / cities: Irvine, California • New Haven, Connecticut • Miami, Florida + 4 more

Search by objective public record fields.

Statins for Acutely Injured Lungs From Sepsis

PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium

Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)

Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Effect of Photobiomodulation on Pain and Healing of the Vertical Releasing Incision After Endodontic Microsurgery

A New Paradigm for Vitamin D Sufficiency

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of Various Cannabinoids on Sleep Quality

HALT Progression of Polycystic Kidney Disease Study A

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

STAT-STatin and Aspirin in Trauma

To Study the Efficacy and Safety of Doxercalciferol on Spinal and Femoral Density in Postmenopausal Osteopenic Women in a Long Term 2 Year Study

Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

Effects of Anorexia Nervosa on Peak Bone Mass

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

Celecoxib After Tonsillectomy

Dexamethasone Dyspnea Study

Statins to Prevent Cancer Associated Blood Clots